What Aiosyn does

Aiosyn is a Dutch medical-software company developing CE-IVDR certified AI algorithms for pathology diagnostics, founded in 2021 and headquartered in Nijmegen, Netherlands. The company builds deep learning computer vision models that analyze histopathology images to automate diagnostic tasks in oncology and nephrology, with a technology base rooted in more than 20 years of academic research at Radboud University Medical Center (Radboudumc).

Aiosyn's product portfolio centers on three solutions: Aiosyn Mitosis Breast, the world's first CE-IVDR certified AI for automated mitosis detection in breast cancer diagnostics, claimed to deliver 60% faster analysis and 32.6% improved consistency versus standard methods; AiosynQC, a pre-scan quality control module that identifies eight or more artifact types before slide imaging; and the NephroPath Platform, an edge-AI research tool capable of analyzing fifteen or more kidney structures for kidney pathology research. The technology is delivered as enterprise software to hospital and independent pathology laboratories, with the flagship product positioned as plug-and-play compatible with existing digital pathology workflows.

Commercially, Aiosyn operates a sales-led, direct enterprise motion targeting pathology labs across Europe through demo-request funnels on aiosyn.org and direct outreach, monetizing through recurring software licensing agreements. The company is privately held and venture-backed, having raised approximately $6.4M cumulatively across a 2022 seed round led by Health Innovations (with LUMO Labs and OostNL), a 2023 EFRO-OOST grant under the AIRAT project with Radboudumc and Pathologie-DNA, and a 2025 round that added TNO Ventures. A 2026 strategic partnership with TNO extends the roadmap into functional and digital biomarker development, while the 2025 spin-off of AIKON Health explores an adjacent cardiac-monitoring vertical.

Name

Aiosyn

Legal name

Aiosyn

Website

https://aiosyn.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Aiosyn is a Nijmegen-based medical-software company that develops CE-IVDR certified deep learning AI for pathology diagnostics, selling enterprise software to European pathology laboratories for breast cancer mitosis detection, pre-scan quality control, and kidney pathology research.

Ownership category

akta.pro rank

Product category

AI Pathology Diagnostics Software

NAICS

Software Publishers (5132), Software Publishers (513210)

SIC

Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Medical Imaging AI (HDAAAEAH), Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)

Keywords

• AI pathology diagnostics
• Medical imaging software
• Computational pathology
• Cancer diagnostics AI
• Digital pathology solutions

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI Pathology Software Licensing: Sale of CE-IVDR certified AI pathology diagnostic software to pathology labs and medical institutions across Europe. Revenue generated through software licensing agreements with healthcare facilities.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Aiosyn develops and sells CE-IVDR certified AI-powered medical software for pathology diagnostics, focusing on automated mitosis detection in breast cancer, pre-scan quality control of pathology slides, and edge AI analysis for kidney pathology research. The software is sold under a SaaS/subscription licensing model to hospital and independent pathology laboratories across Europe, integrating directly into existing digital pathology workflows.

Product overview

Aiosyn offers three CE-IVDR certified AI-powered pathology diagnostic products. Aiosyn Mitosis Breast is the flagship product—the world's first certified AI for automated mitosis detection in breast cancer diagnostics. AiosynQC provides automated pre-scan quality control for artifact detection across 8+ artifact types. The NephroPath Platform delivers edge AI capabilities for advanced kidney pathology research, detecting 15+ kidney structures. Together, these products form a comprehensive AI pathology suite addressing cancer diagnostics, quality assurance, and kidney disease research across European pathology labs.

Differentiator

Problem solved

Functional benefit

Brands

• Aiosyn Mitosis Breast: World's first certified AI for mitosis detection in breast cancer diagnostics
• AiosynQC
• NephroPath Platform

Products and services

• Aiosyn Mitosis Breast World's first CE-IVDR certified AI solution for automated mitosis detection in breast cancer diagnostics, achieving 60% faster analysis and +32.6% improved consistency versus standard methods. Designed for pathology laboratories running digital pathology workflows for breast cancer diagnosis.
• AiosynQC Automated pre-scan quality control software that detects 8+ artifact types before imaging to ensure pathology slide image quality and prevent downstream rework. Built for digital pathology laboratories.
• NephroPath Platform Edge AI platform for advanced kidney pathology research capable of detecting 15+ kidney structures using on-device edge AI processing. Targeted at academic medical centers and research institutions conducting computational nephropathology and biomarker research.

Quantifiable outcome

• 60% faster cancer detection with Aiosyn Mitosis Breast
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• TNO (Netherlands Organization for Applied Scientific Research)flagshipTechnology or Integration · 13 May 2026Strategic technology partnership focused on biomarker innovation for healthcare. TNO, a Dutch independent research organization, partnered with Aiosyn to accelerate development of functional and digital biomarkers. The partnership aims to improve healthcare quality, affordability, and accessibility through AI-driven precision pathology solutions.
• Radboud University Medical CentercoreStrategic or Co-development Partner · 9 May 2023Long-term academic research partnership spanning 20+ years. Radboudumc provides the academic foundation for Aiosyn's AI pathology technology development. The partnership includes joint development of AI-enabled tools for cancer diagnosis under the AIRAT project, with €1.3 million EFRO grant funding.
• Pathologie-DNAcoreStrategic or Co-development Partner · 9 May 2023Collaborative partnership under the AIRAT project to develop AI technology for breast and skin cancer diagnostics. Pathologie-DNA contributes pathology expertise alongside Radboudumc and Aiosyn. The project received €1.3 million EFRO-OOST grant funding for development of CE-marked deep learning algorithms for automated mitosis detection.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Ibex Medical Analytics: Israel-based AI pathology company offering CE-IVD-certified clinical decision-support tools for cancer diagnosis across multiple tissue types. Directly comparable to Aiosyn in product category, regulatory positioning, and target customer (pathology labs).
• Paige: US-based AI pathology company with FDA-authorized products for prostate and breast cancer detection. Comparable to Aiosyn in computer-vision-on-histopathology focus, though operating at significantly larger scale and capital base.
• PathAI: US-based AI pathology platform serving biopharma, diagnostics, and clinical customers with deep-learning tissue analysis. Comparable in technology stack (deep learning on histopathology) and enterprise go-to-market, though much broader in scope.
• Owkin: France-based AI biotech applying machine learning to pathology and clinical research, including federated learning approaches. Comparable in applying AI to histopathology for oncology, with a stronger biopharma-services angle.
• Mindpeak: Hamburg-based AI pathology company offering CE-IVD-marked image-analysis tools for breast and other cancer diagnostics. Closely comparable European peer in product, regulatory positioning, and target pathology-lab customer base.
• Aignostics: Berlin-based AI pathology company spun out from Charité, developing computational pathology models for oncology and biomarker discovery. Comparable in academic origin, European footprint, and AI-on-histopathology focus.
• Proscia: US-based digital pathology platform combining slide management software with AI applications for cancer diagnosis. Comparable in pathology AI focus, though offers a broader enterprise platform versus Aiosyn's point-solution suite.

Broad incumbents

• DeepHealth (RadNet): AI-powered radiology and pathology imaging subsidiary of RadNet, offering FDA-cleared diagnostic algorithms. Comparable as an AI-imaging-diagnostics vendor, though operating in a broader radiology-plus-pathology portfolio with much greater scale.
• Roche (Digital Pathology): Global diagnostics incumbent offering the uPath digital pathology platform and integrated AI partnerships. Comparable as a digital pathology infrastructure provider; though much larger and broader, with potential to acquire or compete against point AI vendors like Aiosyn.

Regional players

• TissueGnostics: Austria-based provider of automated tissue analysis and digital pathology solutions for research and clinical use. Comparable in European pathology AI focus, though with a stronger research-tooling orientation rather than diagnostic SaMD.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aiosyn

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aiosyn